|
|||||
|
|
The Role of Ezetimibe in the Treatment of Cardiovascular Disease |
|
| Authors: | Anandita?Agarwala Zaid?Kajani Michael?D?Miedema |
| Institution: | 1.Health Services Research and Development, Michael E DeBakey Veterans Affairs Medical Center,Houston,USA;2.Department of Medicine,Baylor College of Medicine,Houston,USA;3.Columbia University,New York,USA;4.Minneapolis Heart Institute and Minneapolis Heart Institute Foundation,Minneapolis,USA;5.Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine,Houston,USA;6.Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center,Houston,USA |
| Abstract: | Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |